NCT07504263 is a Phase 1, PHASE2 clinical trial of RP-001 in Advanced Malignancies, sponsored by Recurv Pharma Inc.

Who is sponsoring NCT07504263?

NCT07504263 is sponsored by Recurv Pharma Inc.

What drugs are being tested in NCT07504263?

Interventions in NCT07504263: RP-001.

What condition does NCT07504263 study?

NCT07504263 studies Advanced Malignancies, Oncology, Colorectal Cancer, Pancreatic Cancer, Cancer.

Is NCT07504263 still recruiting?

NCT07504263 is currently not yet recruiting. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT07504263

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

Not yet recruiting Phase 1, PHASE2 Last updated 31 March 2026

What this trial tests

Phase 1, PHASE2 trial testing RP-001 in Advanced Malignancies in 66 participants. Not yet recruiting.

Timeline

23 April 2026

Primary endpoint
1 December 2027

1 April 2028

Quick facts

Lead sponsor	Recurv Pharma Inc
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	23 April 2026
Primary completion	1 December 2027
Estimated completion	1 April 2028

Drugs / interventions tested

RP-001

Conditions studied

Advanced Malignancies — all drugs for Advanced Malignancies →
Oncology — all drugs for Oncology →
Colorectal Cancer — all drugs for Colorectal Cancer →
Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Recurv Pharma Inc — full company profile →

Who can join

18 and older, any sex, with Advanced Malignancies or Oncology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1/2a Study of RP-001 in participants with Advanced Malignancies

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Malignancies

Currently open trials in the same condition.

NCT06937957 — A Study of BR111 in Patients With Advanced Malignancies · Phase 1 · recruiting
NCT06401356 — An Extension Study for Patients Previously Enrolled in Studies With Pelabresib · Phase 3 · recruiting
NCT06468098 — A Study of IBI363 in Subjects With Advanced Malignancies · Phase 1 · recruiting
NCT06717880 — A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer · Phase 1 · recruiting
NCT05059522 — Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07504263 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Recurv Pharma Inc
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07504263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing